Market News

3D Systems (DDD) Reaches $10.46 After 6.00% Up Move; Intra-cellular Therapies (ITCI)’s Sentiment Is 2.77

Intra-Cellular Therapies, Inc., a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including ParkinsonÂ’s and AlzheimerÂ’s disease. The company has market cap of $1.08 billion. The firm is developing its lead drug candidate, lumateperone, known as ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, depression, and other neuropsychiatric and neurological disorders. It currently has negative earnings. Lumateperone, a molecule, is in Phase III clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer's disease.

The stock of 3D Systems Corporation (NYSE:DDD) is a huge mover today! The stock increased 3.05% or $0.31 during the last trading session, reaching $10.46. About 587,247 shares traded. 3D Systems Corporation (NYSE:DDD) has risen 77.31% since February 15, 2017 and is uptrending. It has outperformed by 60.61% the S&P500.The move comes after 6 months positive chart setup for the $1.19B company. It was reported on Feb, 15 by Barchart.com. We have $11.09 PT which if reached, will make NYSE:DDD worth $71.46M more.

Analysts await Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) to report earnings on March, 7. They expect $-0.51 earnings per share, up 20.31% or $0.13 from last year’s $-0.64 per share. After $-0.53 actual earnings per share reported by Intra-Cellular Therapies, Inc. for the previous quarter, Wall Street now forecasts -3.77% EPS growth.

The stock increased 3.49% or $0.67 during the last trading session, reaching $19.86. About 94,298 shares traded. Intra-Cellular Therapies, Inc. (ITCI) has declined 68.76% since February 15, 2017 and is downtrending. It has underperformed by 85.46% the S&P500.

Since January 1, 0001, it had 3 buys, and 9 insider sales for $10.92 million activity.

Ratings analysis reveals 50% of Intra-Cellular Therapies’s analysts are positive. Out of 4 Wall Street analysts rating Intra-Cellular Therapies, 2 give it “Buy”, 0 “Sell” rating, while 2 recommend “Hold”. ITCI was included in 4 notes of analysts from September 29, 2016. The firm earned “Neutral” rating on Thursday, September 29 by SunTrust. The company was downgraded on Thursday, September 29 by JMP Securities. The firm has “Outperform” rating given on Thursday, September 29 by RBC Capital Markets. The stock has “Overweight” rating by Cantor Fitzgerald on Friday, December 16.

Rhenman & Partners Asset Management Ab holds 2.38% of its portfolio in Intra-Cellular Therapies, Inc. for 1.18 million shares. Bvf Inc Il owns 950,000 shares or 1.91% of their US portfolio. Moreover, Bb Biotech Ag has 0.96% invested in the company for 2.20 million shares. The Massachusetts-based Clough Capital Partners L P has invested 0.7% in the stock. Perceptive Advisors Llc, a New York-based fund reported 929,460 shares.

Analysts await 3D Systems Corporation (NYSE:DDD) to report earnings on February, 27. They expect $-0.04 EPS, down 166.67% or $0.10 from last year’s $0.06 per share. After $-0.34 actual EPS reported by 3D Systems Corporation for the previous quarter, Wall Street now forecasts -88.24% EPS growth.

3D Systems Corporation, through its subsidiaries, provides 3D printing services and products worldwide. The company has market cap of $1.19 billion. The companyÂ’s 3D printers transform data input generated by 3D design software, CAD software, or other 3D design tools into printed parts using a range of print materials, including plastic, nylon, metal, composite, elastomeric, wax, polymeric dental materials, and Class IV bio-compatible materials. It currently has negative earnings. It offers various 3D printing technologies, such as stereolithography, selective laser sintering, direct metal printing, multijet printing, and colorjet printing.

Among 19 analysts covering 3D Systems Corporation (NYSE:DDD), 2 have Buy rating, 6 Sell and 11 Hold. Therefore 11% are positive. 3D Systems Corporation had 61 analyst reports since July 22, 2015 according to SRatingsIntel. Gabelli upgraded the stock to “Buy” rating in Friday, November 4 report. The stock of 3D Systems Corporation (NYSE:DDD) has “Sell” rating given on Friday, February 9 by J.P. Morgan. The firm has “Hold” rating given on Thursday, September 21 by Canaccord Genuity. Jefferies maintained 3D Systems Corporation (NYSE:DDD) on Tuesday, March 15 with “Hold” rating. The rating was downgraded by Needham to “Hold” on Tuesday, April 26. As per Sunday, August 9, the company rating was maintained by Needham. The rating was reinitiated by Goldman Sachs with “Neutral” on Tuesday, December 13. On Friday, April 15 the stock rating was downgraded by Citigroup to “Sell”. The firm has “Hold” rating given on Monday, May 29 by Canaccord Genuity. The company was downgraded on Tuesday, March 15 by JP Morgan.

Leave a Reply

Your email address will not be published. Required fields are marked *